Outcomes of relapsed/refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: results from the NCRI AML trials by Hills, R, Gale, R, Linch, D, Huntly, B, Papaemmanuil, E, Vyas, P, Burnett, A, Russell, N

“…American Society of Hematology…”

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML by Knapper, S, Russell, N, Gilkes, A, Hills, RK, Gale, RE, Cavenagh, JD, Jones, G, Kjeldsen, L, Grunwald, MR, Thomas, I, Konig, H, Levis, MJ, Burnett, AK

“…American Society of Hematology…”

Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis by Dillon, R, Jovanovic, J, Potter, N, Foot, N, Ahearne, M, Jayne, S, Dennis, M, Hunter, A, Dyer, M, Vyas, P, Quek, L, Russell, N, Hills, R, Solomon, E, Grimwade, D

“…American Society of Hematology…”

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials by Gale, R, Popa, T, Wright, M, Khan, N, Freeman, S, Burnett, A, Russell, N, Hills, R, Linch, D

“…American Society of Hematology…”

Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia by Burnett, A, Russell, N, Hills, R

“…American Society of Hematology…”